Pazyar Nader, Yaghoobi Reza, Zeynalie Maryam, Vala Samin
Dermatology Department, Ahvaz Jundishapur University of Medical Science, Ahvaz, Iran.
Dermatology Department, Emam Hospital, School of Medicine, Ahvaz University of Medical Science, Ahvaz, Iran,
Clin Cosmet Investig Dermatol. 2019 Feb 14;12:115-122. doi: 10.2147/CCID.S191964. eCollection 2019.
Melasma is a common benign acquired pigmentary dermatosis due to a disorder in the function of the melanogenesis process. Although several treatments are currently used, it remains a great challenge.
The aim of this study is to compare the efficacy of intradermal injected tranexamic acid (TA) vs hydroquinone (HQ) cream in the treatment of melasma.
In this prospective split face controlled clinical trial, 49 patients were randomly divided into two groups of A (24 persons) and B (25 persons). Patients received TA intradermal injections every 2 weeks on the right side of the face with a concentration of 4 mg/ mL in group A and a concentration of 10 mg/mL in group B. The left side in both groups was treated twice daily with topical 4% HQ cream, and treatment continued for 12 weeks in both groups. Melasma Area and Severity Index (MASI) scores were measured for each side of the face at baseline and at weeks 4, 8, 12, and 24. SPSS, version 22, <0.05, was used for data analysis.
Forty-one patients (21 in group A and 20 in group B) completed the study. The MASI score in the 12th week significantly decreased compared to the baseline for group A, group B, and HQ cream. However, no statistically significant difference was observed between the MASI score of patients in groups A and B. Also, the comparison of TA at the concentration of 4 mg/ mL compared to the 4% HQ cream showed that the MASI scores in the eighth week (=0.02) and the 12th week (=0.02) were significantly less in the HQ group. However, no significant difference was observed between the MASI score changes in Group B (10 mg/mL) and the 4% HQ group. Also, patients in group A had higher satisfaction than patients in group B (=0.001).
Injection of TA intradermally can be an effective treatment for melasma.
黄褐斑是一种常见的良性获得性色素沉着性皮肤病，由于黑素生成过程功能紊乱所致。尽管目前有多种治疗方法，但它仍然是一个巨大的挑战。
本研究旨在比较皮内注射氨甲环酸（TA）与氢醌（HQ）乳膏治疗黄褐斑的疗效。
在这项前瞻性半脸对照临床试验中，49例患者被随机分为A组（24人）和B组（25人）。A组患者每2周在右侧面部皮内注射浓度为4mg/mL的TA，B组浓度为10mg/mL。两组左侧均每日外用4%HQ乳膏治疗两次，两组均持续治疗12周。在基线、第4、8、12和24周时测量面部两侧的黄褐斑面积和严重程度指数（MASI）评分。使用SPSS 22版，<0.05进行数据分析。
41例患者（A组21例，B组20例）完成了研究。A组、B组和HQ乳膏组第12周的MASI评分与基线相比均显著降低。然而，A组和B组患者的MASI评分之间未观察到统计学显著差异。此外，4mg/mL浓度的TA与4%HQ乳膏相比，HQ组在第8周（=0.02）和第12周（=0.02）的MASI评分显著更低。然而，B组（10mg/mL）和4%HQ组的MASI评分变化之间未观察到显著差异。此外，A组患者的满意度高于B组（=0.001）。
皮内注射TA可有效治疗黄褐斑。
